ADC Therapeutics (ADCT)
NYSE Market Closed
ADC Therapeutics SA is a commercial-stage biotechnology company developing cancer treatments based on antibody-drug conjugate technology. The company focuses on therapies designed to deliver potent cancer-killing agents directly to tumor cells by linking them to antibodies that recognize specific targets. This approach aims to improve anti-tumor activity while limiting some effects on healthy tissue, although oncology drugs in this class can still carry significant safety risks.
The company’s lead marketed medicine is ZYNLONTA, also known as loncastuximab tesirine. It is a CD19-directed antibody-drug conjugate approved by the US Food and Drug Administration for certain adult patients with relapsed or refractory large B-cell lymphoma after two or more prior lines of systemic therapy. This places ADC Therapeutics in the market for difficult-to-treat hematologic cancers, where patients often have limited options after standard therapies fail.
Beyond its commercial product, ADC Therapeutics maintains a clinical and preclinical development pipeline aimed at expanding the use of its platform across blood cancers and solid tumors. Programs referenced by the company include studies such as LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, which explore different treatment settings, combinations, or targets in oncology.
Revenue is primarily tied to the commercialization of ZYNLONTA, with the United States representing the company’s largest market, followed by regions including Europe, the Middle East, and Africa. As a biotechnology stock, ADCT is shaped by product sales, clinical trial results, regulatory decisions, competition from other lymphoma therapies, manufacturing execution, and the company’s ability to fund research while advancing its pipeline.
Last updated
- Market Cap
- 403.2M
- P/E
- —
- P/FCF
- —
- P/S
- 5.09
- Enterprise Value
- 287.86M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- BIOPOLE, EPALINGES, V8, 1066
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Graphic Packaging Holding Company - GPK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - A US$ 50 Billion+ Market Opportunity By 2030
ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt
Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
ADC Therapeutics tritt demnächst den Indizes Russell 2000® und Russell 3000® bei
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics nimmt an der Jefferies Global Healthcare Conference teil
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
ADC Therapeutics wird an der H.C. Wainwright 2nd Annual BioConnect Investor Conference an der NASDAQ teilnehmen
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
ADC Therapeutics nimmt an der RBC Capital Markets Global Healthcare Conference 2024 teil
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
ADC Therapeutics veröffentlicht die Finanzergebnisse des ersten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsverlauf bekannt
ADC Therapeutics kündigt garantiertes Angebot an Stammaktien und Pre-Funded Warrants im Umfang von USD 105 Mio. an
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 403.2M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 287.86M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -1.86
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 5.09
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -2.75
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 3.64
- EPS
- -1.08
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -114.58M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 63.31%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -47%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- -0.53
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.09
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 4.02
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 3.42
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.04M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 3.17
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 20.85M | 23.06M | 16.43M | 18.84M | 23.03M |
| Gross profit | 17.24M | 21.36M | 15.23M | 18M | 20.97M |
| Operating income | -25.25M | -17.92M | -30.97M | -44.15M | -28.46M |
| EBITDA | -25.25M | -18.27M | -30.59M | -30.69M | -28.46M |
| Net income | -32.97M | -6.41M | -40.97M | -56.65M | -38.6M |
| Basic EPS | -0.21 | 0.02 | -0.3 | -0.5 | -0.36 |
| Diluted EPS | -0.21 | 0.02 | -0.3 | -0.5 | -0.36 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 291.5M | 323.15M | 289.76M | 321.56M | 272.54M |
| Total liabilities | 507.87M | 508.98M | 527.94M | 520.75M | 510.76M |
| Total equity | -216.38M | -185.83M | -238.18M | -199.18M | -238.22M |
| Cash & equivalents | 231.01M | 261.34M | 234.74M | 264.56M | 194.7M |
| Current assets | 276.77M | 306.34M | 287.15M | 318.76M | 257.99M |
| Current liabilities | 67.63M | 70.16M | 62.04M | 64.6M | 57.79M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -29.71M | -31.12M | -29.63M | -24.09M | -56.33M |
| Investing cash flow | -32K | 659K | 0 | 0 | -264K |
| Financing cash flow | -583K | 57.09M | -198K | 93.78M | 271K |
| Change in cash | -30.33M | 26.63M | -29.83M | 69.7M | -56.33M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — ADC Therapeutics SA | View Filing | |
| edgar index | 10-Q — ADC Therapeutics SA | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — ADC Therapeutics SA | View Filing | |
| edgar index | DEFA14A — ADC Therapeutics SA | View Filing | |
| edgar index | DEF 14A — ADC Therapeutics SA | View Filing | |
| edgar index | 424B3 — ADC Therapeutics SA | View Filing | |
| edgar index | PRE 14A — ADC Therapeutics SA | View Filing | |
| edgar index | SCHEDULE 13G/A — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| form 4 | Form 4 — Redmile Group, LLC | View Filing | |
| form 4 | Form 4 — RedCo II Master Fund, L.P. | View Filing | |
| form 4 | Form 4 — RedCo II Master Fund, L.P. | View Filing | |
| form 4 | Form 4 — Green Jeremy | View Filing | |
| form 4 | Form 4 — Green Jeremy | View Filing | |
| form 4 | Form 4 — Redmile Group, LLC | View Filing | |
| form 4 | Form 4 — Redmile Group, LLC | View Filing | |
| form 4 | Form 4 — RedCo II Master Fund, L.P. | View Filing | |
| form 4 | Form 4 — RedCo II Master Fund, L.P. | View Filing | |
| form 4 | Form 4 — Green Jeremy | View Filing | |
| form 4 | Form 4 — Green Jeremy | View Filing | |
| form 4 | Form 4 — Redmile Group, LLC | View Filing | |
| form 4 | Form 4 — RedCo II Master Fund, L.P. | View Filing | |
| form 4 | Form 4 — Redmile Group, LLC | View Filing | |
| form 4 | Form 4 — Green Jeremy | View Filing | |
| form 4 | Form 4 — RedCo II Master Fund, L.P. | View Filing | |
| form 4 | Form 4 — Redmile Group, LLC | View Filing | |
| form 4 | Form 4 — Green Jeremy | View Filing | |
| edgar index | 424B3 — ADC Therapeutics SA | View Filing | |
| edgar index | EFFECT — ADC Therapeutics SA | View Filing | |
| edgar index | UPLOAD — ADC Therapeutics SA | View Filing | |
| edgar index | CORRESP — ADC Therapeutics SA | View Filing | |
| edgar index | S-3 — ADC Therapeutics SA | View Filing | |
| edgar index | 8-K — ADC Therapeutics SA | View Filing | |
| edgar index | 10-K — ADC Therapeutics SA | View Filing | |
| edgar index | ARS — ADC Therapeutics SA | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — ADC Therapeutics SA | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| edgar index | SCHEDULE 13G/A — ADC Therapeutics SA | View Filing | |
| edgar index | SCHEDULE 13G/A — ADC Therapeutics SA | View Filing | |
| edgar index | SCHEDULE 13G/A — ADC Therapeutics SA | View Filing | |
| edgar index | SCHEDULE 13G — ADC Therapeutics SA | View Filing | |
| edgar index | SCHEDULE 13G/A — ADC Therapeutics SA | View Filing | |
| form 4 | Form 4 — MALLIK AMEET | View Filing | |
| form 4 | Form 4 — MALLIK AMEET | View Filing | |
| form 4 | Form 4 — MALLIK AMEET | View Filing | |
| form 4 | Form 4 — Carmona Jose | View Filing | |
| form 4 | Form 4 — Carmona Jose | View Filing | |
| form 4 | Form 4 — GRAHAM PETER J | View Filing | |
| form 4 | Form 4 — GRAHAM PETER J | View Filing | |
| form 4 | Form 4 — Zaki Mohamed | View Filing | |
| form 4 | Form 4 — Zaki Mohamed | View Filing | |
| form 4 | Form 4 — Kallebo Lisa Michelle | View Filing | |
| form 4 | Form 4 — Kallebo Lisa Michelle | View Filing | |
| edgar index | 8-K — ADC Therapeutics SA | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ADC Therapeutics SA | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B3 — ADC Therapeutics SA | View Filing | |
| edgar index | EFFECT — ADC Therapeutics SA | View Filing | |
| edgar index | CORRESP — ADC Therapeutics SA | View Filing | |
| edgar index | S-3/A — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing | |
| edgar index | 4 — ADC Therapeutics SA | View Filing |